Publication date: Available online 24 September 2018
Source: Auris Nasus Larynx
Author(s): Yaxuan Liu, Yangyang Ying, Jaffar S. Pandu, Yan Wang, Shuang Dou, Yanzhong Li, Dedong Ma
Abstract
Objective
We have designed the expiratory positive airway pressure (EPAP) mask to provide a new sort of therapeutic strategies for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS). And this study aims to assess the safety, efficacy and compliance of the EPAP therapy.
Methods
40 healthy volunteers were enrolled to measure the end-tidal carbon dioxide pressure (PETCO2) while being treated by EPAP mask. 40 symptomatic moderate or severe OSAHS patients (AHI ≥ 15/h) recruited were equally divided into two groups randomly and treated with CPAP or mask for a week respectively. After a week of washing out, the patients were applied with exchanged therapeutic methods for another week. The PSG was performed at the end of each week of treatment with device-on.
Results
There were no significant differences of PETCO2 under different exhaled positive pressure level between CPAP, EPAP therapies and non-therapy for the healthy volunteers (P > 0.05). After being treated, among the OSAHS patients in the two groups, the ESS scores and AHI decreased, and minimum SaO2 and mean SaO2 increased significantly (all P > 0.05). There was no significant differences of the efficacy between EPAP and CPAP therapy.
Conclusions
EPAP mask therapy was safe and reliable with significant efficacy for selected OSAHS patients. However, the compliance needs further improvement.
https://ift.tt/2zsxRL6
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου